Ramipril
Vostally
Angiotensin Converting Enzyme Inhibitor
NADAC/unit
$0.0527
No Shortage
Tier 1: 293.0%
8 Manufacturers
31 ANDAs
vs. brand Vostally: Generic saves up to 99% per unit
Market Intelligence
2024-11-27 Class II Recall: Lupin Pharmaceuticals Inc.
2024-11-27 Class II Recall: Lupin Pharmaceuticals Inc.
2024-11-27 Class II Recall: Lupin Pharmaceuticals Inc.
Generic Manufacturers
AUROBINDO PHARMA LTDCHARTWELL MOLECULAR HOLDINGS LLCCOREPHARMA LLCHIKMA PHARMACEUTICALS USA INCLUPIN LTDROSEMONT PHARMACEUTICALS HOLDINGS INCSENORES PHARMACEUTICALS INCWATSON LABORATORIES INCZYDUS PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.